RxDoctor Payments Data

Mary Kuehler, APRN

Psychiatric/Mental Health · Norfolk, NENPI 1093118325

Payments from drug & device makers

$971in general payments, 2019–2025

Across 55 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$219
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$200
  • AbbVie$171
  • Otsuka America Pharmaceutical, Inc.$147
  • Teva Pharmaceuticals USA, Inc.$84
  • Alkermes, Inc.$81
  • plus $69 from 3 others

What the payments were for

  • Food & beverage$92495%
  • Education$475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$971 in reported general payments places this provider in the 50th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$40,784
Medicare patients
55
Services billed
548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine35$371,940
Invega TrinzaPaliperidone Palmitate22$222,652
Abilify AsimtufiiAripiprazole36$208,395
Invega SustennaPaliperidone Palmitate66$194,652
CaplytaLumateperone Tosylate95$177,127
IngrezzaValbenazine Tosylate11$90,735
Abilify MaintenaAripiprazole13$36,505
Seroquel XrQuetiapine Fumarate13$24,495
VraylarCariprazine Hcl12$17,411
Lurasidone Hcl121$15,608
Clozapine226$13,008
TrintellixVortioxetine Hydrobromide13$8,806
Desvenlafaxine Succinate ErDesvenlafaxine Succinate106$5,665
SeroquelQuetiapine Fumarate13$5,113
Prazosin Hcl197$4,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$219$417,30488 claims
Teva Pharmaceuticals USA, Inc.Austedo$84$371,94035 claims
Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena$147$244,89949 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$200$177,12795 claims
AbbVieVraylar$171$17,41112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Norfolk

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →